Issuance of new Hong Kong patent strengthens intellectual property protection for Jaguar Health in the treatment of short bowel syndrome (SBS) Page 1

New patent issued for core target indication for rare disease for crofelemer

Napo has approximately 230 patents granted and pending

Jaguar is supporting independent, investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications SBS and microvillus inclusion disease (MVID), an ultra-rare congenital diarrheal disorder (CDD), in the US, EU and Middle East/North Africa regions, with results expected in late 2024 and throughout 2025.